Please try another search
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Name | Age | Since | Title |
---|---|---|---|
Sean Stalfort | 52 | 2018 | Independent Chairman of the Board |
Jeffrey L. C. Ives | 71 | 2014 | Independent Director |
Kimberlee Cobleigh Drapkin | 54 | 2022 | Independent Director |
Laura Stoppel | 36 | 2020 | Independent Director |
Nathan B. Fountain | 60 | 2021 | Independent Director |
Jeffrey L. Cummings | 73 | - | Member of Clinical & Scientific Advisory Board |
Reisa Sperling | - | - | Member of Clinical & Scientific Advisory Board |
Stephen Salloway | - | - | Member of Clinical & Scientific Advisory Board |
Cynthia A. Lemere | - | - | Member of Clinical & Scientific Advisory Board |
Colin Louis Masters | 76 | - | Member of Clinical & Scientific Advisory Board |
Derrell D. Porter | 52 | 2023 | Independent Director |
Lennart Mucke | - | 2022 | Member of the Scientific Advisory Board |
Michael A. Weiner | 76 | - | Member of Clinical & Scientific Advisory Board |
Steven T. DeKosky | - | - | Member of Clinical & Scientific Advisory Board |
Daniel J. O'Connell | 53 | 2006 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review